Glioblastoma Multiforme Clinical Trials

37 studies are recruiting for glioblastoma multiforme in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

   This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drug…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Run by

   Leland Metheny

   See if you can join NCT05052957 on ClinicalTrials.gov

2. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

3. HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

   This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-…

   Stage

   Phase 1

   Ages

   3 to 22

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   3 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT03911388 on ClinicalTrials.gov

4. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

   The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   9 in total

   Run by

   Boston Scientific Corporation

   See if you can join NCT05303467 on ClinicalTrials.gov

5. Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

   Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a nov…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Northwestern University

   See if you can join NCT05864534 on ClinicalTrials.gov

6. Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

   This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins. The information from this study may help scientists develop new tests to m…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00083512 on ClinicalTrials.gov

7. A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

   This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet inte…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   5 in total

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT05708352 on ClinicalTrials.gov

8. Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

   The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Health Herbert Wertheim Cancer Institute, Miami, Florida

   Locations

   2 in total

   Run by

   Baptist Health South Florida

   See if you can join NCT06991101 on ClinicalTrials.gov

9. Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

   Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in peop…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Neurological Disorders and Stroke (NINDS)

   See if you can join NCT07416188 on ClinicalTrials.gov

10. Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

    Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona

    Locations

    2 in total

    Run by

    University of Arizona

    See if you can join NCT06814496 on ClinicalTrials.gov

11. Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning

    This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05864976 on ClinicalTrials.gov

12. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

    The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

    Stage

    EARLY_Phase 1

    Ages

    1 to 21

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Locations

    18 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT06333899 on ClinicalTrials.gov

13. Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

    The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Li…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    2 in total

    Run by

    Aveta Biomics, Inc.

    See if you can join NCT06011109 on ClinicalTrials.gov

14. Loupe-Based Intraoperative Fluorescence Imaging

    Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technolo…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of Kentucky, Lexington, Kentucky

    Run by

    Guoqiang Yu

    See if you can join NCT04780009 on ClinicalTrials.gov

15. Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

    The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT01269853 on ClinicalTrials.gov

16. Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05271240 on ClinicalTrials.gov

17. Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

    This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05954858 on ClinicalTrials.gov

18. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

    This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05979064 on ClinicalTrials.gov

19. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

    The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

    Stage

    Phase 2

    Ages

    1 to 39

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Locations

    20 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05843253 on ClinicalTrials.gov

20. IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

    This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Florida Health, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05353530 on ClinicalTrials.gov

21. Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

    This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05281731 on ClinicalTrials.gov

22. Sonodynamic Therapy in Patients With Recurrent GBM

    Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. F…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    Shayan Moosa, MD

    See if you can join NCT06039709 on ClinicalTrials.gov

23. Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

    The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administra…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05366179 on ClinicalTrials.gov

24. HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

    Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Houston Methodist Neurological Institute, Houston, Texas

    Run by

    David Baskin MD

    See if you can join NCT03596086 on ClinicalTrials.gov

25. Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

    To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for research will be collected from three different regions within the same tumor to study how these regions differ in their structure, DNA, and RNA…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

    Run by

    Baptist Health South Florida

    See if you can join NCT05756985 on ClinicalTrials.gov